WINNIPEG, Manitoba — August 5, 2026 — Leads & Copy — Kane Biotech Inc. (TSX-V: KNE) has retained DNA Advisors Inc. as its exclusive financial advisor to conduct a comprehensive review of strategic opportunities aimed at increasing shareholder value and advancing the company’s long-term growth. The process will explore various alternatives, including strategic partnerships, financing initiatives, business development, acquisitions, and commercial collaborations.
Kane Biotech’s products, revyve® Antimicrobial Wound Gel and Antimicrobial Wound Gel Spray, have received U.S. Food and Drug Administration (FDA) 510(k) clearance and Health Canada approval. Commercial activities in both the United States and Canada began in 2026 with the addition of senior business development personnel.
Philip Renaud, Chairman of Kane Biotech, stated that the company has established a strong position in biofilm science and advanced wound care, achieving significant commercial and clinical milestones. He believes this is an opportune moment to review strategic options that could strengthen the company and enhance shareholder value. Renaud expressed pleasure in working with DNA Advisors to evaluate potential opportunities and engage with parties that could support Kane’s next development phase.
Dr. Robert Huizinga, Interim Chief Executive Officer of Kane Biotech, affirmed the company’s commitment to executing commercial objectives while simultaneously assessing initiatives for additional shareholder value creation. He highlighted Kane’s solid foundation, built on scientific expertise, intellectual property, expanding commercial activities, and growing market awareness of biofilm management in wound care. Huizinga added that the review process is designed to ensure the company pursues the most advantageous opportunities for long-term success.
Kane Biotech cautioned that there is no guarantee the strategic review will result in any specific transaction or outcome. The company has not set a timetable for the review and will not disclose developments unless the Board of Directors approves a course of action or disclosure is required by securities laws.
Kane Biotech is focused on commercializing and developing innovative wound care treatments that disrupt biofilms and improve healing. Biofilms are a major contributor to antibiotic resistance in wounds, leading to severe clinical outcomes and substantial costs. The revyve product line targets both biofilms and wound bacteria. revyve Antimicrobial Wound Gel, revyve Antimicrobial Wound Gel Spray, and revyve Antimicrobial Skin and Wound Cleanser are cleared by the U.S. FDA, and the wound gel and spray versions are also approved by Health Canada. More information can be found at revyvegel.com or revyvegel.ca.
Source: Kane Biotech Inc.
